Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-10T08:22:24.520Z Has data issue: false hasContentIssue false
  • English
  • Français

Risk factors and outcomes associated with community-onset and hospital-acquired coinfection in patients hospitalized for coronavirus disease 2019 (COVID-19): A multihospital cohort study

Part of: SARS-CoV-2/COVID-19

Published online by Cambridge University Press:  26 July 2021

Lindsay A. Petty Open the ORCID record for Lindsay A. Petty [Opens in a new window] ,
Scott A. Flanders ,
Valerie M. Vaughn ,
David Ratz ,
Megan O’Malley ,
Anurag N. Malani ,
Laraine Washer ,
Tae Kim ,
Keith E. Kocher  and
Scott Kaatz
...Show all authors
Lindsay A. Petty*
Affiliation:
Division of Infectious Diseases, Internal Medicine, University of Michigan, Ann Arbor, Michigan
Scott A. Flanders
Affiliation:
Division of Hospital Medicine, Internal Medicine, University of Michigan, Ann Arbor, Michigan
Valerie M. Vaughn
Affiliation:
Division of General Internal Medicine, Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah
David Ratz
Affiliation:
Division of Hospital Medicine, Internal Medicine, University of Michigan, Ann Arbor, Michigan
Megan O’Malley
Affiliation:
Division of Hospital Medicine, Internal Medicine, University of Michigan, Ann Arbor, Michigan
Anurag N. Malani
Affiliation:
Division of Infectious Diseases, Internal Medicine, St. Joseph Mercy Health System, Ann Arbor, Michigan
Laraine Washer
Affiliation:
Division of Infectious Diseases, Internal Medicine, University of Michigan, Ann Arbor, Michigan
Tae Kim
Affiliation:
Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan
Keith E. Kocher
Affiliation:
Emergency Medicine and Learning Health Sciences, University of Michigan, Ann Arbor, Michigan
Scott Kaatz
Affiliation:
Division of Hospital Medicine, Henry Ford Hospital, Detroit, Michigan
Tawny Czilok
Affiliation:
Division of Hospital Medicine, Internal Medicine, University of Michigan, Ann Arbor, Michigan
Elizabeth McLaughlin
Affiliation:
Division of Hospital Medicine, Internal Medicine, University of Michigan, Ann Arbor, Michigan
Hallie C. Prescott
Affiliation:
Division of Pulmonary and Critical Care, Internal Medicine, University of Michigan and VA Center for Clinical Management Research, Ann Arbor, Michigan
Vineet Chopra
Affiliation:
Division of Hospital Medicine, Internal Medicine, University of Michigan, Ann Arbor, Michigan
Tejal Gandhi*
Affiliation:
Division of Infectious Diseases, Internal Medicine, University of Michigan, Ann Arbor, Michigan
*
Author for correspondence: Lindsay A. Petty, E-mail: pettyl@med.umich.edu. Or Tejal N. Gandhi, E-mail: tgandhi@med.umich.edu
Author for correspondence: Lindsay A. Petty, E-mail: pettyl@med.umich.edu. Or Tejal N. Gandhi, E-mail: tgandhi@med.umich.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

We sought to determine the incidence of community-onset and hospital-acquired coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19) and to evaluate associated predictors and outcomes.

Methods:

In this multicenter retrospective cohort study of patients hospitalized for COVID-19 from March 2020 to August 2020 across 38 Michigan hospitals, we assessed prevalence, predictors, and outcomes of community-onset and hospital-acquired coinfections. In-hospital and 60-day mortality, readmission, discharge to long-term care facility (LTCF), and mechanical ventilation duration were assessed for patients with versus without coinfection.

Results:

Of 2,205 patients with COVID-19, 141 (6.4%) had a coinfection: 3.0% community onset and 3.4% hospital acquired. Of patients without coinfection, 64.9% received antibiotics. Community-onset coinfection predictors included admission from an LTCF (OR, 3.98; 95% CI, 2.34–6.76; P < .001) and admission to intensive care (OR, 4.34; 95% CI, 2.87–6.55; P < .001). Hospital-acquired coinfection predictors included fever (OR, 2.46; 95% CI, 1.15–5.27; P = .02) and advanced respiratory support (OR, 40.72; 95% CI, 13.49–122.93; P < .001). Patients with (vs without) community-onset coinfection had longer mechanical ventilation (OR, 3.31; 95% CI, 1.67–6.56; P = .001) and higher in-hospital mortality (OR, 1.90; 95% CI, 1.06–3.40; P = .03) and 60-day mortality (OR, 1.86; 95% CI, 1.05–3.29; P = .03). Patients with (vs without) hospital-acquired coinfection had higher discharge to LTCF (OR, 8.48; 95% CI, 3.30–21.76; P < .001), in-hospital mortality (OR, 4.17; 95% CI, 2.37–7.33; P ≤ .001), and 60-day mortality (OR, 3.66; 95% CI, 2.11–6.33; P ≤ .001).

Conclusion:

Despite community-onset and hospital-acquired coinfection being uncommon, most patients hospitalized with COVID-19 received antibiotics. Admission from LTCF and to ICU were associated with increased risk of community-onset coinfection. Future studies should prospectively validate predictors of COVID-19 coinfection to facilitate the reduction of antibiotic use.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 43 , Issue 9 , September 2022 , pp. 1184 - 1193
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Morris, DE, Cleary, DW, Clarke, SC. Secondary bacterial infections associated with influenza pandemics. Front Microbiol 2017;8:1041.CrossRefGoogle ScholarPubMed
Rawson, TM, Moore, LSP, Zhu, N, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020;71:2459–2468.Google ScholarPubMed
Vaughn, VM, Gandhi, T, Petty, LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with COVID-19: a multi-hospital cohort study. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa1239.CrossRefGoogle Scholar
Karaba, SM, Jones, G, Helsel, T, et al. Prevalence of coinfection at the time of hospital admission in COVID-19 patients, a multicenter study. Open Forum Infect Dis 2020. doi:10.1093/ofid/ofaa578.CrossRefGoogle Scholar
Zhou, F, Yu, T, Du, R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–1062.CrossRefGoogle ScholarPubMed
Vaughn, VM, Flanders, SA. Reply to Stevenson et al. Clin Infect Dis 2021;72:e927.CrossRefGoogle Scholar
Could efforts to fight the coronavirus lead to overuse of antibiotics? Pew Trusts website. https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2021/03/could-efforts-to-fight-the-coronavirus-lead-to-overuse-of-antibiotics. Published 2021. Accessed June 24, 2021.Google Scholar
Clancy, CJ, Nguyen, MH. COVID-19, superinfections, and antimicrobial development: What can we expect? Clin Infect Dis 2020;71:2736–2743.CrossRefGoogle ScholarPubMed
Garcia-Vidal, C, Sanjuan, G, Moreno-García, E, et al. Incidence of coinfections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 2021;27:83–88.CrossRefGoogle ScholarPubMed
Lansbury, L, Lim, B, Baskaran, V, Lim, WS. Coinfections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020;81:266–275.CrossRefGoogle ScholarPubMed
Antimicrobial resistance in the age of COVID-19. Nature Microbiol 2020;5:779.CrossRefGoogle Scholar
Vaughn, VM, Flanders, SA, Snyder, A, et al. Excess antibiotic treatment duration and adverse events in patients hospitalized with pneumonia: a multihospital cohort study. Ann Intern Med 2019;171:153–163.CrossRefGoogle ScholarPubMed
Petty, LA, Vaughn, VM, Flanders, SA, et al. Risk factors and outcomes associated with treatment of asymptomatic bacteriuria in hospitalized patients. JAMA Intern Med 2019;179:1519–1527.CrossRefGoogle ScholarPubMed
Bloodstream infection event. Central line-associated bloodstream infection and non-central line-associated bloodstream infection. Centers for Disease Control and Prevention website. http://www.cdc.gov/nhsn/PDFs/pscManual/4PSC_CLABScurrent.pdf. Accessed January 2016.Google Scholar
Buckland, ST, Burnham, KP, Augustin, NH. Model selection: an integral part of inference. Biometrics 1997;53:603–618.CrossRefGoogle Scholar
Brandt, ME, Harrison, LH, Pass, M, et al. Candida dubliniensis fungemia: the first four cases in North America. Case reports. Emerg Infect Dis 2000;6:46–9.CrossRefGoogle Scholar
Assiri, A, Al-Tawfiq, JA, Al-Rabeeah, AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013;13:752–761.CrossRefGoogle ScholarPubMed
Bhatraju, PK, Ghassemieh, BJ, Nichols, M, et al. COVID-19 in critically ill patients in the Seattle region—case series. N Engl J Med 2020;382:2012–2022.CrossRefGoogle ScholarPubMed
Somers, EC, Eschenauer, GA, Troost, JP, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis 2021;73:e445–e454.CrossRefGoogle ScholarPubMed
Marr, KA PA, Tornheim, JA, et al. Aspergillosis complicating severe coronavirus disease. Emerg Infect Dis 2021;27:18–25.CrossRefGoogle ScholarPubMed
Supplementary material: File

Petty et al. supplementary material

Petty et al. supplementary material

Download Petty et al. supplementary material(File)
File 16.2 KB